4D Molecular Therapeutics Secures Major Financial Deal - TipRanks.com - TipRanks
| FDMT Stock | USD 3.47 0.05 1.46% |
Slightly above 50% of 4D Molecular's private investors are presently thinking to get in. The analysis of the overall investor sentiment regarding 4D Molecular Therapeutics suggests that some traders are interested. 4D Molecular's investing sentiment can be driven by a variety of factors including economic data, 4D Molecular's earnings reports, geopolitical events, and overall market trends.
4D Molecular Therapeutics Secures Major Financial Deal - TipRanks.com TipRanks
Read at news.google.com
 |
4D Molecular Fundamental Analysis
We analyze 4D Molecular's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of 4D Molecular using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of 4D Molecular based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Equity
Return On Equity Comparative Analysis
4D Molecular is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
4D Molecular Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with 4D Molecular stock to make a market-neutral strategy. Peer analysis of 4D Molecular could also be used in its relative valuation, which is a method of valuing 4D Molecular by comparing valuation metrics with similar companies.
Peers
4D Molecular Related Equities
| GOSS | Gossamer Bio | 3.57 | ||||
| STOK | Stoke Therapeutics | 0.75 | ||||
| CGEM | Cullinan Oncology | 0.38 | ||||
| REPL | Replimune | 0.12 | ||||
| MLYS | Mineralys Therapeutics, | 0.75 | ||||
| BDTX | Black Diamond | 1.00 | ||||
| AKRO | Akero Therapeutics | 1.48 | ||||
| EWTX | Edgewise Therapeutics | 1.55 | ||||
| NVCT | Nuvectis Pharma | 1.73 | ||||
| IPSC | Century Therapeutics | 1.75 | ||||
| BMEA | Biomea Fusion | 2.11 | ||||
| PASG | Passage Bio | 2.70 | ||||
| KRON | Kronos Bio | 2.90 | ||||
| LYRA | Lyra Therapeutics | 4.36 | ||||
| RVMD | Revolution Medicines | 5.13 | ||||
| CCCC | C4 Therapeutics | 8.70 |
Additional Tools for FDMT Stock Analysis
When running 4D Molecular's price analysis, check to measure 4D Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 4D Molecular is operating at the current time. Most of 4D Molecular's value examination focuses on studying past and present price action to predict the probability of 4D Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 4D Molecular's price. Additionally, you may evaluate how the addition of 4D Molecular to your portfolios can decrease your overall portfolio volatility.